Book Chapter10.1007/978-1-4471-6648-1_13
Emerging Therapies in Rheumatoid Arthritis
Ian C. Scott,James Galloway,David Scott +2 more
- 01 Jan 2015
- pp 183-190
8
TL;DR: This chapter will provide an overview of the emerging therapeutic options for RA patients, spanning biosimilars, Janus Kinase inhibitors, other kinase inhibitor, PDE4 inhibitors and future potential therapeutic targets such as IL-17 inhibition.
read more
Abstract: The high costs of biologic agents, allied to the fact that not all patients will respond to them, means there is a major research focus on developing novel treatments for RA patients. One solution to these high costs is the development of “biosimilar” drugs. These are biological products that are highly similar to existing licensed biologics, allowing for minor differences in clinically inactive components, and for which there are no clinically meaningful differences in terms of product safety, purity, and potency. Another solution that would address both cost and non-responders is the development of small molecule agents, which target cellular structures and intracellular signalling proteins such as Janus Kinases. This chapter will provide an overview of the emerging therapeutic options for RA patients, spanning biosimilars, Janus Kinase inhibitors, other kinase inhibitors, PDE4 inhibitors and future potential therapeutic targets such as IL-17 inhibition.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
Marc Feldmann,Ravinder N. Maini +1 more
TL;DR: Clinical investigations in which the activity of TNF alpha in RA patients was blocked with intravenously administered infliximab, a chimeric anti-TNF alpha monoclonal antibody (mAB), has provided evidence that TNF regulates IL-6, IL-8, MCP-1, and VEGF production, recruitment of immune and inflammatory cells into joints, angiogenesis, and reduction of blood levels of matrix metalloproteinases-1 and -3.
1.3K
Abandoned therapies and unpublished trials in rheumatoid arthritis
TL;DR: Researchers have provided extremely valuable lessons in study design, immunobiology, pharmacodynamic evaluation, and the utility of animal models in the development of biologic agents that have laid the groundwork for future development of other novel therapeutic agents in the treatment of rheumatoid arthritis.
50
European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib.
TL;DR: Tofacitinib has been shown to reduce symptoms of RA and improve the quality of life in the analyzed groups of patients and was the first JAK inhibitor approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) in the RA therapy, thus providing a useful alternative treatment strategy.
[IL-1Ra: its role in rheumatoid arthritis].
TL;DR: Since anti TNF-alpha therapy is not effective in all RA patients, nor does it fully control the arthritic process in affected joints of good responders, the combined treatment with intermediate doses of TNF and IL-1 blockers, reaching synergistic suppression of arthritis, seems warranted in RA.
Quantitative predictive modelling approaches to understanding rheumatoid arthritis: A brief review
TL;DR: In this article, the authors reviewed various quantitative predictive modelling approaches for understanding rheumatoid arthritis. And they highlighted models aimed at optimising the costs of the treatments while taking into consideration the evolution of the disease and potential complications.
14
References
Biosimilars of Biological Drug Therapies Regulatory, Clinical and Commercial Considerations
TL;DR: The clinical, safety and submission requirements for biosimilars in several major markets are reviewed, issues of ongoing debate amongst key stakeholders are highlighted and some of the commercial challenges faced by developers of biosimilar are examined.
117
The advent of biosimilar therapies in rheumatology—“O Brave New World”
Morton Scheinberg,Jonathan Kay +1 more
TL;DR: The development of biosimilar therapies for the treatment of patients with rheumatic diseases could potentially result in substantial cost savings for patients and health care providers, and consequently, increased availability of effective therapies.
109
Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Michael E. Weinblatt,Mark C. Genovese,Meilien Ho,Sally Hollis,Krystyna Rosiak-Jedrychowicz,Arthur Kavanaugh,David Millson,Gustavo Leon,Millie Wang,Désirée van der Heijde +9 more
TL;DR: This phase III, 52‐week study compared fostamatinib with placebo (for 24 weeks) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX) therapy.
102